e-learning
resources
Munich 2006
Tuesday 05.09.2006
COPD therapy
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Tiotropium reduces the risk of COPD exacerbation irrespective of its characterization by the treatment intervention
D. M. G. Halpin, S. Menjoge, K. Viel (Exeter, United Kingdom; Ridgefield, United States Of America; Ingelheim, Germany)
Source:
Annual Congress 2006 - COPD therapy
Session:
COPD therapy
Session type:
Oral Presentation
Number:
4397
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. M. G. Halpin, S. Menjoge, K. Viel (Exeter, United Kingdom; Ridgefield, United States Of America; Ingelheim, Germany). Tiotropium reduces the risk of COPD exacerbation irrespective of its characterization by the treatment intervention. Eur Respir J 2006; 28: Suppl. 50, 4397
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Late Breaking Abstract - Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19 (BREATH study)
Related content which might interest you:
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma.
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020
The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history
Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Year: 2019
QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015
QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Influence of statin therapy on exacerbation frequency in patients with COPD
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
COPD exacerbations: impact and prevention
Source: Breathe 2013; 9: 434-440
Year: 2013
Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Phenotype-based therapy of COPD: Effect on the rate of COPD exacerbations
Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD?
Year: 2018
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Impact of roflumilast treatment on the rate and duration of exacerbations and overall steroid load in patients with COPD
Source: Annual Congress 2011 - COPD management
Year: 2011
Decaf score for predicting treatment escalation in exacerbations of COPD
Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD
Year: 2020
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV
1
in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma
Source: Eur Respir J, 55 (1) 1900964; 10.1183/13993003.00964-2019
Year: 2020
QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Efficiency of different approaches for the assessment of the risk of exacerbations in patients with COPD
Source: International Congress 2019 – Airway disease-associated exacerbations
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept